Kringle Pharma Full Year 2024 Earnings: JP¥118 loss per share (vs JP¥158 loss in FY 2023)
Kringle Pharma (TSE:4884) Full Year 2024 Results
Key Financial Results
- Net loss: JP¥756.0m (loss narrowed by 12% from FY 2023).
- JP¥118 loss per share (improved from JP¥158 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Kringle Pharma shares are up 3.1% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 5 warning signs for Kringle Pharma (2 make us uncomfortable!) that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Kringle Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4884
Kringle Pharma
Engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines.
Flawless balance sheet moderate.
